• Sellas Life Sciences is trading 8.9% up at $14.27 today, fueled by significant institutional buying and the nearing final analysis of its pivotal Phase 3 REGAL trial for acute myeloid leukemia.
  • Goldman Sachs, alongside other institutions like Jefferies, Susquehanna, Jones Financial, Bank of America, and Wellington Management, expanded their positions in SLS.
  • The company's CEO confirmed preparations for a database lock as the REGAL trial has recorded 78 of the 80 events required to trigger its final analysis.
  • Shares advanced from $11.04 on August 10 to $13.10 on August 18, demonstrating a strong upward trend leading into today's surge.